This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

3rd ed, by William A. Sibley, 212 pp, $13.95, New York, NY, Demos Publications, 1992.

G. C. Ebers, MD, FRCPC, Reviewer
London, Ontario

Arch Neurol. 1994;51(8):746-747.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

This useful book is now in its third edition. It has been revised from previous editions by the larger and expanded therapeutic claims committee of the International Federation of Multiple Sclerosis (MS) Societies. This is composed of several well-known MS clinician-investigators, drawn from a worldwide constituency, and the information in this paperback represents their consensus. Although the committee might profit from including a clinical trial methodologist who could provide a non-MS perspective, this volume continues the fine tradition established in the first edition. The historical section, which was such an interesting feature in the first edition, has been abridged, but what is left still provides a sobering perspective on the fads and fancies of the last decades of MS therapy.

The proper design of an MS clinical trial is reemphasized with the appropriate stress placed on, for example, blinding and randomizations. These serve as a good background for the evaluation . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?